Investors Investors

Stock Quote

NASDAQ: PGNX
$7.75
- 0.38
4:00 PM ET on April 21

Press Releases

All Releases
View Summary Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 20, 2017
PDF 10.5 KB Add to Briefcase
View Summary Progenics Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
Mar 30, 2017
PDF 9.4 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA®
Mar 30, 2017
PDF 17.4 KB Add to Briefcase
View Summary Data from Phase 2 Study of Progenics' PSMA-Targeted Imaging Agent 1404 Published in Journal of Nuclear Medicine
Mar 24, 2017
PDF 58.8 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update
Mar 9, 2017
PDF 75.2 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial Results Call for March 9
Feb 23, 2017
PDF 9.5 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted Therapeutic Candidate 1095 For the Treatment of Metastatic Prostate Cancer
Feb 14, 2017
PDF 11.6 KB Add to Briefcase
View Summary Progenics Pharmaceuticals, Inc. to Participate in February Investor Conferences
Feb 8, 2017
PDF 12.1 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Announces Independent Committee's Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404
Dec 22, 2016
PDF 58.7 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Announces First Patient Dosed in Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™
Dec 7, 2016
PDF 11.5 KB Add to Briefcase
View Summary Progenics Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 8, 2016
PDF 12.2 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results and Business Update
Nov 7, 2016
PDF 74.3 KB Add to Briefcase
View Summary Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing
Nov 7, 2016
PDF 62.0 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Sets Third Quarter 2016 Financial Results Call for November 7
Oct 24, 2016
PDF 10.4 KB Add to Briefcase
View Summary Progenics Pharmaceuticals to Present at the 23rd Annual Prostate Cancer Foundation Scientific Retreat
Oct 21, 2016
PDF 10.6 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial
Sep 7, 2016
PDF 11.1 KB Add to Briefcase
View Summary Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets
Sep 6, 2016
PDF 59.1 KB Add to Briefcase
View Summary Progenics Pharmaceuticals to Present at the 23rd Annual NewsMakers in the Biotech Industry Conference
Sep 2, 2016
PDF 10.4 KB Add to Briefcase
View Summary Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results
Aug 4, 2016
PDF 73.7 KB Add to Briefcase
View Summary Progenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain
Jul 26, 2016
PDF 60.3 KB Add to Briefcase
Showing 1-20 of 282 Page: 1 2 3 4 5 ... 15  Next 20
Add to Briefcase = add release to Briefcase